A Phase 2 interventional study of Oxaliplatin and capecitabine [Xeloda] in Gastric Cancer, sponsored by Hoffmann-La Roche. Completed at 13 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies testing oxaliplatin in Stomach Neoplasms — 18 open to participants now, 23 under way, 6 of them phase 3. Oxaliplatin · Stomach Neoplasms.
Among the 131 studies testing oxaliplatin in Stomach Neoplasms, this one is the 74th largest by enrollment of the 129 interventional ones that give a count, is one of 9 that started in 2007, is one of 77 in phase 2, and was the 17th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.
Browse Stomach Neoplasms studies →18 of the 131 studies testing oxaliplatin in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 18–80
AstraZeneca · Sites in United States, Canada, China and 8 more countries
Ages 18+
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
Ukrainian Society of Clinical Oncology · Sites in Lithuania, Ukraine
Ages 18–80
RemeGen Co., Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 89 · Phase 3 24 · Phase 4 3
First in 1998; this study’s year is marked. 9 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 66 across 2,500 interventional studies indexed under Stomach Neoplasms.
Median enrollment 51 across the 129 interventional studies. Of the 74 that completed or were terminated, 24 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 131 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
29 studies in Stomach Neoplasms by Hoffmann-La Roche: none open now, 2 under way, none of them phase 3. Of 27 finished, 15 (56%) have results posted.
Among the 29 studies in Stomach Neoplasms by Hoffmann-La Roche, this one is the 16th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2007, is one of 11 in phase 2, and was the 1st registered.
Hoffmann-La Roche’s Stomach Neoplasms studies by the year they started, since 2003.
4 of the studies testing oxaliplatin in Stomach Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06028737Phase 3Ukrainian Society of Clinical OncologyTotal Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer | 2027-04-25 |
| NCT07257575Guangdong Provincial People's HospitalA Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma | 2027-01-31 |
| NCT05184803Asan Medical CenterA Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer | 2027-06-30 |
| NCT07069712AstraZenecaA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | 2027-11-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 131 studies testing oxaliplatin in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 29 in Stomach Neoplasms:
This tab as a report to print or save as PDF → With an account.
This single arm study will assess the efficacy and safety of Xeloda in combination with oxaliplatin as first-line chemotherapy in patients with advanced and/or metastatic gastric cancer who have had no prior chemotherapy for advanced or metastatic disease. Eligible patients will receive Xeloda 1000mg/m2 po twice daily, D1-D10 every 2 weeks (10 days treatment followed by 4 days rest period) plus oxaliplatin 85 mg/m2/day iv, D1 every 2 weeks. The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Oxaliplatin · Drug: capecitabine [Xeloda]
85mg/m2 iv on day 1 of each 2 week cycle
1000mg/m2 po bid on days 1-10 of each 2 week cycle
Overall response rate
Time frame: Event driven
Time to disease progression, overall survival, duration of response, time to response.
Time frame: Event driven
AEs, laboratory parameters.
Time frame: Throughout study
The record gives a start of Mar 2007, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxaliplatin